Hall S.R.
45
Coauthors
4
Documentos
Volumen de publicaciones por año
| Año de publicación | Num. Publicaciones |
|---|---|
| 2022 | 4 |
Publicaciones por áreas de conocimiento
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Inmunología | 4 |
| Biotecnología | 2 |
| Infección | 2 |
| Farmacología | 1 |
| Descubrimiento de fármacos | 1 |
Publicaciones por áreas temáticas
| Área temática | Num. Publicaciones |
|---|---|
| Microorganismos, hongos y algas | 3 |
| Farmacología y terapéutica | 2 |
| Medicina y salud | 1 |
| Fisiología y materias afines | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 4 |
| Google Scholar | 0 |
| RRAAE | 0 |
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Alsolaiss J. | 4 |
| Edge R.J. | 4 |
| Stefanie K. Menzies | 4 |
| Harrison R.A. | 4 |
| Crittenden E. | 4 |
| Casewell N.R. | 4 |
| Dawson C.A. | 2 |
| Wilkinson M.C. | 2 |
| Ainsworth S. | 2 |
| Westhorpe A. | 2 |
Top Keywords
Publicaciones del autor
Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition
ArticleAbstract: Antivenom is currently the first-choice treatment for snakebite envenoming. However, only a low propPalabras claves:Autores:Ainsworth S., Alsolaiss J., Casewell N.R., Crittenden E., Dawson C.A., Edge R.J., Hall S.R., Harrison R.A., Stefanie K. Menzies, Wilkinson M.C.Fuentes:scopusExploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms
ArticleAbstract: Snakebite is a neglected tropical disease that causes high rates of global mortality and morbidity.Palabras claves:antivenom, immunogen, neglected tropical diseases, polyclonal antibodies, recombinant expression, serine proteases, snake venom toxin, snakebiteAutores:Ainsworth S., Alomran N., Alsolaiss J., Blundell P., Casewell N.R., Crittenden E., Dawson C.A., Edge R.J., Hall S.R., Harrison R.A., Stefanie K. Menzies, Wilkinson M.C.Fuentes:scopusIn vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus
ArticleAbstract: Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming byPalabras claves:Boomslang, drugs, Small molecules, snakebite, SVMPAutores:Alsolaiss J., Casewell N.R., Clare R.H., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Kool J., Marriott A.E., Stefanie K. Menzies, Westhorpe A., Xie C.Fuentes:scopusTwo snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
ArticleAbstract: Background Snakebite is a major public health concern in Eswatini, where treatment relies upon one aPalabras claves:Autores:Alsolaiss J., Casewell N.R., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Lalloo D.G., Litschka-Koen T., Murray J., Padidar S., Pons J., Shongwe N., Stefanie K. Menzies, Thomas B., Westhorpe A.Fuentes:scopus